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Abstract
Background: The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus
allowing patients with 20–30 % bone marrow blasts (AML20–30, formerly MDS-RAEB-t) to be categorised and
treated as either MDS or AML. In addition, an artificial distinction between AML20–30 and AML30+ was made by
regulatory agencies by initially restricting approval of azacitidine to AML20–30. Thus, uncertainty prevails regarding
the diagnosis, prognosis and optimal treatment timing and strategy for patients with AML20–30. Here, we aim to
provide clarification for patients treated with azacitidine front-line.
Methods: The Austrian Azacitidine Registry is a multicentre database (ClinicalTrials.gov: NCT01595295). For this
analysis, we selected 339 patients treated with azacitidine front-line. According to the WHO classification 53, 96 and
190 patients had MDS-RAEB-I, MDS-RAEB-II and AML (AML20–30: n = 79; AML30+: n = 111), respectively. According
to the FAB classification, 131, 101 and 111 patients had MDS-RAEB, MDS-RAEB-t and AML, respectively.
Results: The median ages of patients with MDS and AML were 72 (range 37–87) and 77 (range 23–93) years,
respectively. Overall, 80 % of classifiable patients (≤30 % bone marrow blasts) had intermediate-2 or high-risk IPSS
scores. Most other baseline, treatment and response characteristics were similar between patients diagnosed with
MDS or AML. WHO-classified patients with AML20–30 had significantly worse OS than patients with MDS-RAEB-II
(13.1 vs 18.9 months; p = 0.010), but similar OS to patients with AML30+ (10.9 vs 13.1 months; p = 0.238). AML patients
that showed MDS-related features did not have worse outcomes compared with patients who did not (13.2 vs
8.9 months; p = 0.104). FAB-classified patients with MDS-RAEB-t had similar survival to patients with AML30+ (12.8 vs
10.9 months; p = 0.376), but significantly worse OS than patients with MDS-RAEB (10.9 vs 24.4 months; p < 0.001).
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Conclusions: Our data demonstrate the validity of the WHO classification of MDS and AML, and its superiority over the
former FAB classification, for patients treated with azacitidine front-line. Neither bone marrow blast count nor presence
of MDS-related features had an adverse prognostic impact on survival. Patients with AML20–30 should therefore be
regarded as having ‘true AML’ and in our opinion treatment should be initiated without delay.
Keywords: AML, MDS, WHO, FAB, Classification, RAEB-t, Bone marrow blast count, Azacitidine, Austrian Azacitidine
Registry
Background
Since 1982, patients with 20–30 % bone marrow blasts
have been considered to have myelodysplastic syndromes
with refractory anaemia and excess blasts in transformation
(MDS-RAEB-t) according to the French-American-British
(FAB) classification [1]. When the World Health
Organization (WHO) classification came into effect in
2001, these patients were considered to have acute
myeloid leukaemia (AML) with a low bone marrow
blast count (hereafter AML20–30; Additional file 1:
Table S1) [1, 2]. This new classification (updated in
2008 [3]) was driven by novel insights from several
studies that identified that bone marrow blast count
had more prognostic weight than was originally per-
ceived and that MDS-RAEB-t patients had similar out-
comes to patients with AML and more than 30 %
bone marrow blasts (hereafter AML30+), partly owing
to the fact that MDS-RAEB-t commonly transformed
into AML [4–12].
Although the sum of available data led the WHO to
conclude that AML20–30 (formerly MDS-RAEB-t) and
AML30+ were essentially the same disease 15 years ago,
several relevant groups do not appear to consider the
scientific evidence to be strong enough: (i) The National
Comprehensive Cancer Network (NCCN) endorses both
FAB and WHO classification systems, allowing MDS-
RAEB-t to be diagnosed and treated as either MDS or
AML [13, 14]; (ii) many large phase III randomised clin-
ical trials still retain MDS-RAEB-t as an MDS sub-entity
[15]; and (iii) while the division of the category MDS-
RAEB into RAEB-I and RAEB-II by WHO was validated
and generally accepted to add significant prognostic
value [16–18], scientific debate regarding the abandon-
ment of the sub-entity MDS-RAEB-t by WHO remains
between members of the MDS Study Group [19], the
WHO Myeloid Disease Writing and Clinical Advisory
Committees [20], and between other renowned experts
in the field [21, 22]. Therefore, uncertainty prevails re-
garding the diagnosis, prognosis, and optimal treatment
timing and strategy for patients with AML20–30.
Azacitidine was approved for the treatment of patients
with MDS and AML20–30 in 2004 by the Food and
Drug Agency (FDA) and in 2008 by the European Medi-
cines Agency (EMA). Although the patient population
included in clinical trial protocols resulting in drug ap-
proval included up to 38 % of patients with AML30+
(CALGB-protocols 8921 and 9221) [23], both the FDA
and the EMA restricted approval of azacitidine to
AML20–30, and a further large randomised clinical trial
was required to prove the efficacy of azacitidine in
AML30+. This artificial distinction between AML20–30
and AML30+ was made by the regulatory agencies and
reflects neither the former FAB classification of MDS-
RAEB-t (which could also be diagnosed if bone marrow
blasts were <20 % with the presence of >4 % peripheral
blood blasts or Auer rods) nor the current WHO classifica-
tion of MDS and AML. Azacitidine treatment for patients
with AML30+ was off-label until very recently (30 October
2015), when the EMA extended the indication for azaciti-
dine to include this patient subgroup. Approval was mainly
based on the results of a phase III randomised trial per-
formed exclusively in AML30+ patients [24]. While bone
marrow blast percentage has retrospectively been analysed
in smaller patient cohorts for its potential as a prognostic
factor for AML patients treated with azacitidine front-line
[25, 26], no in-depth analysis of patient baseline characteris-
tics, treatment characteristics and outcomes exist. To date,
no clinical trial has directly compared the efficacy of azaciti-
dine in AML patients with 20–30 % vs >30 % bone marrow
blasts, a gap we aimed to bridge.
In this study, we provide the first comparison of base-
line characteristics and outcomes of patients with MDS
and AML treated with azacitidine front-line, with the
intention to (i) provide further insight into the efficacy
of azacitidine in the subgroup of AML patients for
whom this drug was initially approved (i.e. AML20–30)
and to assess whether patients with AML30+ benefit
from azacitidine treatment in a similar way to patients
with AML20–30; (ii) evaluate the potential prognostic
relevance of the presence of MDS-related features (MRF)
in AML and (iii) assess the outcomes of patients with
MDS and AML as classified by both the WHO and FAB
systems, in order to clarify whether elderly, intensive
chemotherapy (IC)-ineligible patients with AML20–30
(formerly RAEB-t) should be regarded and treated as
having MDS or AML. To answer these questions, this
analysis focuses on the differences in morphological
features (blast count in peripheral blood and/or bone
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We identified 339 patients from the Austrian Azacitidine
Registry (AAR) who had been diagnosed with MDS-
RAEB-I/II or AML according to the WHO classification
and treated with azacitidine as a front-line agent. Of
these, 149 patients had MDS, of which 53 had RAEB-I
and 96 had RAEB-II; 190 patients had AML. Among AML
patients, 79 had AML20–30 and 111 had AML30+. The
median age of patients with MDS was 72 (range 37–87)
years, and the median age of patients with AML was 77
(range 23–93) years (Table 1). Only four patients were
<40 years, three of which proceeded to allogeneic stem cell
transplantation, and one of which died while on treatment
with azacitidine (Additional file 2: Table S2). A total of 4,
44, 35 and 4 % of patients with MDS-RAEB-I had a low,
intermediate-1, intermediate-2 or high International
Prognostic Scoring System (IPSS) risk score, whereas 0,
9, 42 and 34 % of patients with MDS-RAEB-II had a
low, intermediate-1, intermediate-2 or high IPSS risk
score, and 0, 0, 14 and 85 % of patients with AML20–30
had a low, intermediate-1, intermediate-2 or high IPSS
risk score, respectively. This score is not applicable to
AML patients with more than 30 % bone marrow blasts.
Of patients diagnosed with WHO-AML, 7, 4, 71 and 19 %
had therapy-related AML, AML with recurrent cytogen-
etic abnormalities, AML-MRF and AML not otherwise
specified, respectively.
When patients were reclassified according to FAB, 131,
101 and 111 patients had MDS-RAEB, MDS-RAEB-t and
AML, respectively.
Azacitidine front-line in AML20–30 vs AML30+
Baseline characteristics were compared in patients
with AML30+ and AML20–30 treated with azacitidine
front-line. There was no significant difference in median
age, gender distribution, presence of MRF, frequency of
therapy-related AML, median peripheral blood blasts,
Eastern Cooperative Oncology Group performance status
(ECOG PS), IPSS cytogenetic risk group, red blood cell
(RBC) and platelet (PLT) transfusion dependence (TD),
median haemoglobin (Hb) levels and PLT, white blood cell
(WBC) or absolute neutrophil count (ANC) (Table 1).
Azacitidine treatment characteristics were also compared
between cohorts. No significant difference was observed for
the median number of treatment cycles received or median
azacitidine dose per cycle (Table 2). The percentage of pa-
tients receiving ≥6 cycles, ≥12 cycles, 7 days of azacitidine
and the EMA target dose of 75 mg/m2 d1-7 did not differ
significantly between cohorts and neither did patient status
at data cut-off (Table 2). The median number of cycles for
patients with AML30+ vs AML20–30 was 5 vs 6 cycles for
the total subgroups, 10 vs 9 cycles for responding patients
and 2 vs 3.5 cycles for non-responding patients, respectively
(Table 2). However, a trend towards a higher percentage of
patients receiving fewer than 3 cycles of azacitidine was ob-
served in the AML30+ subgroup (29 vs 17 %, p = 0.069;
Table 2). This may reflect the observations that adverse
events (AEs) were more often the cause for azacitidine
discontinuation (12 vs 4 %; p = 0.045; Table 2), grade 3–4
infections occurred more often (50 vs 32 %; p = 0.047) and
there was a trend for higher rates of febrile neutropenia
(23 vs 13 %; p = 0.075) and 60-day mortality (15 vs 6 %;
p = 0.053) in the AML30+ subgroup compared with
AML20–30 (Table 3).
Overall response rate (ORR; defined as CR, complete
cytogenetic response [CyCR], CR with incomplete blood
count recovery [CRi], partial response [PR]), haemato-
logical improvement (HI) and achievement of transfu-
sion independence (TI) were similar between patients
with AML30+ and AML20–30; 30-day mortality rates
were low (8 vs 6 %); 1-year survival rates (50 vs 56 %)
and median OS (10.9 vs 13.1 months) were relatively
high and did not differ significantly between AML30+
and AML20–30, respectively (Tables 3 and 4 and Fig. 1a).
This remained true when analysing patients with MRF
(13.1 vs 13.5 months, p = 0.474; Table 5 and Fig. 1b).
Impact of MDS-related features in AML
No negative impact was observed for the presence of
MRF in AML patients, irrespective of bone marrow blast
count. Median OS was 13.1 vs 9.0 months (p = 0.142) for
patients with AML30+ with vs without MRF; 13.5 vs
8.8 months (p = 0.464) for patients with AML20–30 with
vs without MRF; and 13.2 vs 8.9 months (p = 0.104) for
all AML patients with vs without MRF (Fig. 2a–c).
Impact of the WHO classification on the distinction
between MDS and AML
In order to see whether we could validate the WHO
classification in patients treated with azacitidine front-line,
we compared baseline and treatment characteristics, as well
as the occurrence of treatment-emergent AEs (TEAEs), re-
sponse, and outcomes in patients with AML20–30 and
MDS-RAEB-II, as well as between patients with MDS-
RAEB-II and MDS-RAEB-I, in addition to the comparison
between AML30+ and AML20–30 detailed above (Tables 1,
2, 3, 4 and 5).
The AML20–30 cohort had a higher proportion of pa-
tients older than 75 years (60 vs 39 %; p = 0.034), patients
had a higher PLT count (66 vs 44G/L; p = 0.036) and a
trend for a higher proportion of patients with elevated
baseline peripheral blood blasts (65 vs 45 %; p = 0.058)
than the RAEB-II cohort, respectively. No significant dif-
ferences in baseline characteristics could be found when
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Table 1 Comparison of baseline characteristics of patients with WHO-MDS or WHO-AMLreceiving azacitidine front-line
AML30+ (n = 111) AML20–30 (n = 79) p value AML20–30 (n = 79) RAEB-II (n = 96) p value RAEB-II (n = 96) RAEB-I (n = 53) p value
AZA first-line, % 100 100 1 100 100 1 100 100 1
Age (years), median (range)



















Male, % 55.0 65.6 0.334 65.6 65.6 1 65.6 77.4 0.323
MRFa, % 66.7 78.5 0.327 78.5 100b 0.110 100b 100b 1
Therapy-related, % 4.5 8.9 0.229 8.9 9.4 0.906 9.4 11.3 0.677






































































































RBC-TD, % 55.9 48.1 0.444 48.1 55.2 0.485 55.2 67.9 0.252
PLT-TD, % 27.9 21.5 0.363 21.5 31.3 0.177 31.3 22.6 0.236
Hb (g/dL), median (range) 9.1 (5.8–14.2) 9.1 (6.3–13.4) 1 9.1 (6.3–13.4) 9.1 (6.7–14.2) 1 9.1 (6.7–14.2) 8.9 (2.5–15) 0.964
PLT (G/L), median (range) 50 (7–1270) 66 (6–1100) 0.137 66 (6–1100) 44 (7–1184) 0.036 44 (7–1184) 51 (8–610) 0.473
WBC (G/L), median (range) 2.5 (0.6–96.0) 2.5 (0.6–41.6) 1 2.5 (0.6–41.6) 2.5 (0.8–96.0) 1 2.5 (0.8–96.0) 2.5 (0.6–13.8) 1
ANC (G/L), median (range) 0.5 (0–37.2) 0.7 (0–28.0) 0.856 0.7 (0–28.0) 0.9 (0–42.0) 0.874 0.9 (0–42.0) 1.1 (0.2–10.9) 0.888
aMRF: MDS-related features, as defined by presence of MDS-related cytogenetics (MRC) and/or antecedent haematological disease (AHD) and/or myelodysplasia
bFor the diagnosis of MDS according to WHO, the presence of myelodysplasia is required in all patients (i.e. 100 %)
cThe IPSS cytogenetic risk score was established for and validated in patients with MDS and is not commonly used to stratify cytogenetic risk in AML patients. However, we used this score for both MDS and AML
patients, in order to be able to compare frequencies of karyotypes across these patient groups
WHO World Health Organization, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, RAEB refractory anaemia with excess blasts, AZA azacitidine, PB peripheral blood, ECOG PS Eastern Cooperative















Table 2 Comparison of treatment characteristics of patients with WHO-MDS or WHO-AML receiving azacitidine front-line
AML30+ (n = 111) AML20–30 (n = 79) p value AML20–30 (n = 79) RAEB-II (n = 96) p value RAEB-II (n = 96) RAEB-I (n = 53) p value






































































AZA 7 daysa, % 75.4 78.9 0.779 78.9 69.2 0.426 69.2 71.1 0.872
EMA target dosea, b, % 63.5 62.8 0.950 62.8 59.0 0.730 59.0 43.4 0.123




























































































Dead at data cut-off





























aRegards total azacitidine (AZA) cycles applied to the whole cohort (n = 508 [RAEB-I], n = 893 [RAEB-II], n = 715 [AML20–30], n = 111 [AML30+])
b75 mg/m2 d1–7
















Table 3 Comparison of TEAEsa,b and response of WHO MDS and WHO AML patients receiving azacitidine front-line
TEAEsa AML30+ (n = 111) AML20–30 (n = 79) p value AML20–30 (n = 79) RAEB-II (n = 96) p value RAEB-II (n = 96) RAEB-I (n = 53) p value
TE-thrombocytopeniab G3–4, % 40.5 41.8 0.885 41.8 35.4 0.466 35.4 39.6 0.628
TE-neutropeniab G3–4, % 35.3 39.2 0.488 39.2 32.3 0.414 32.3 41.5 0.284
TE-anaemiab G3–4, % 47.8 53.2 0.591 53.2 54.2 0.924 54.2 47.2 0.487
Febrile neutropenia, % 23.4 12.7 0.075 12.7 8.3 0.337 8.3 10.3 0.643




















































HI without marrow responsec, % 22.5 16.5 0.337 16.5 24.0 0.239 24.0 32.1 0.279
RBC-TIc, % 43.6 42.1 0.872 42.1 28.3 0.100 28.3 58.3 <0.001
PLT-TIc, % 38.7 47.1 0.365 47.1 43.3 0.689 43.3 58.3 0.137
Outcome
30-day mortality, % 8.1 6.3 0.635 6.3 3.1 0.297 3.1 0.0 0.078
60-day mortality, % 15.3 6.3 0.053 6.3 5.2 0.746 5.2 1.9 0.216
1-year survival (total cohort), % 49.6 55.7 0.552 55.7 70.8 0.179 70.8 81.1 0.403
Median overall survival, months 10.9 13.1 0.238 13.1 18.9 0.010 18.9 23.7 0.302
aTEAEs were defined as new or worsening AEs between the time of first dose to the end of the safety follow-up period (28 days after the last dose of azacitidine)
bTE haematological toxicity was calculated from differential blood counts and transfusions status of all cycles for each patient (no missing data)
cHaematological improvement (HI) and achievement of transfusion independence (TI) was assessed according to IWG 2006 criteria. HI and TI are not considered as a form of response in the current AML response
criteria but were additionally assessed in AML patients, in order to compare the efficacy of azacitidine across disease entities
TEAE treatment emergent (TE) adverse event (AE), WHO World Health Organization, MDS myelodysplastic syndrome, AML acute myeloid leukaemia, RAEB refractory anaemia with excess blasts, G grade, ORR overall
















comparing the MDS-RAEB-II with the MDS-RAEB-I co-
hort (Table 1). There were no differences in treatment
characteristics or the occurrence of TEAEs between pa-
tients with AML20–30 and MDS-RAEB-II or between
MDS-RAEB-II and MDS-RAEB-I, respectively (Tables 2
and 3). However, in comparison with patients with
AML20–30, a significantly higher proportion of patients
with MDS-RAEB-II were still on azacitidine (6 vs 24 %, p
= 0.001), still alive (16 vs 51 %, p < 0.001) and correspond-
ingly fewer had died (84 vs 49 %; p = 0.003) at study cut-
off, respectively (Table 2). No such differences were ob-
served between the MDS-RAEB-II and MDS-RAEB-I co-
horts, respectively (Table 2).
Although ORR and HI were comparable between all
four cohorts, a higher complete response (CR) rate was
observed in AML20–30 compared with MDS-RAEB-II
(17 vs 5 %, p = 0.015), which may reflect the presence of
residual myelodysplasia in patients with MDS: bone
marrow blast count reduction to <5 %, normalisation of
peripheral blood cell counts and lack of dysplasia are re-
quired for the definition of CR in MDS according to
International Working Group (IWG) 2000 [27], but not
for the definition of CR in AML [28]. However, the im-
plications of residual dysplasia in patients with MDS or
AML who otherwise meet the criteria for CR remain un-
clear [13, 28].
Despite higher CR rates in AML20–30, median OS
was significantly worse as compared with MDS-RAEB-II
(13.1 vs 18.9 months, p = 0.010; Tables 3 and 4; Fig. 1a).
The same held true when considering only those AML
patients that had MRF (13.5 vs 18.9 months; p = 0.033;
Table 5 and Fig. 1b). However, OS of those patients that did
achieve CR was much longer for patients with RAEB-II
(59.0 months), as compared to patients with AML20–30
achieving CR (18.4 months).
Why higher CR rate in AML20–30 did not translate
into longer OS of the total cohort remains speculative at
this time point. It was stated by IWG in 2006 that ‘al-
though it is logical that a complete cytogenetic response,
as in AML, would also prolong survival in MDS, there
are presently little data to support this assumption’ [13].
Furthermore, it is becoming widely accepted that while
CR remains the main treatment goal in elderly MDS and
AML patients treated with hypomethylating agents, it
does not seem to be a prerequisite for survival benefit in
MDS (e.g. Gore SD, Haematologica 2013) or AML [24,
29, 30]. Previous reports of MDS patients treated with
intensive chemotherapy [31–33] or decitabine [34] have
also observed higher CR rates for patients with RAEB-t
compared with other ‘lower-risk’ MDS patients. The
shorter OS (9.0 vs 16.6 months; p = 0.021), despite
higher CR rates in RAEB-t as compared with other types
of MDS observed in the latter analysis, may be due to
shorter duration of response (5.0 vs 9.9 months; p =
0.024) [34]. The same group also observed shorter OS
(13.9 vs 18.6 months, p = 0.022) despite similar re-
sponse rates (27 vs 27 %, p > 0.05) in MDS patients that
transformed to AML, compared to those that did not
[35]. One must also bear in mind that CR only occurs in a
minority of patients treated with hypomethylating agents.
Therefore, small differences in CR rates (16.5 % in
AML20-30 vs 5.2 % in MDS-RAEB-II), even if they are
statistically significant, do not necessarily have to translate
into longer median OS for the whole cohort. The adverse
prognosis of having AML (rather than MDS) thus seems
to outweigh the benefits of slightly higher CR rate.
In patients with MDS-RAEB-I, we observed a higher
proportion of patients with the intention to proceed to
allogeneic stem cell transplantation (p = 0.012; Table 2),
a higher proportion of patients achieving RBC-TI (p <
0.001; Table 3) and a trend for lower 30-day mortality
(p = 0.078; Table 3) compared with patients with MDS-
RAEB-II; 1-year survival rates and median OS were not
significantly different between these two subgroups (Ta-
bles 3 and 5; Fig. 1a). Time to treatment from first cyto-
penias or first diagnosis was shorter for patients with
AML compared with MDS (Additional file 3: Table S3).
Median cycles to the first response or best response, as
well as duration of response, were similar for all four dis-
ease categories. However, patients with MDS-RAEB-I
seemed to have longer relapse- and event-free survival, as
well as time from azacitidine stop to death, than patients
with MDS-RAEB-II, AML20–30 or AML30+, respectively
(Additional file 3: Table S3).
Impact of the FAB classification on the distinction
between MDS and AML
When patients were classified according to FAB criteria,
patients with RAEB-t had similar survival to patients
with AML30+ (12.8 vs 10.9 months, p = 0.376), but sig-
nificantly worse OS than patients with MDS-RAEB (12.8
vs 24.4 months, p < 0.001; Table 6; Fig. 1c).
Table 4 WHO classification: OS of patients with MDS or AML
receiving azacitidine front-line













































aHR = 1.292; 95 % CI 1.168, 1.430
bHR = 1.645; 95 % CI 1.123, 2.409
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Fig. 1 Overall survival of MDS and AML patients treated with azacitidine front-line within the AAR. a Patients classified according to WHO criteria.
b Patients with MRF classified according to WHO criteria. c Patients classified according to FAB criteria
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Discussion
To date, no clinical trial has been performed that specif-
ically assessed the efficacy of azacitidine in the AML pa-
tient subgroup for which the drug was initially approved,
namely AML20–30 (formerly MDS-RAEB-t). Depending
on the classification system used to distinguish MDS
from AML, AML20–30 was either grouped together
with high-risk MDS (FAB classification) or AML (WHO
classification). The only available clinical trial data spe-
cific to the AML20–30 subgroup of patients treated with
azacitidine is based on sub-analyses of the AZA-MDS-001
trial and the CALGB protocol 8421, which had low
AML20–30 patient numbers (n = 53 and n = 24) [23, 36].
In addition, one retrospective analysis from the Dutch
named patient programme published data on 38 AML20–
30 patients treated with azacitidine, but 13 % of these had
relapsed/refractory AML [37]. We therefore present data
from the largest cohort of patients with AML20–30 treated
with azacitidine front-line (n = 79) to date. Outcomes were
encouraging with an ORR of 34 % and a median OS of
13.1 months, especially taking the advanced age of this co-
hort into consideration (median age 77 years with 60 %
>75 years). In comparison, patients with AML20–30 in-
cluded within former clinical trials were younger (me-
dian ages were 65, 70 and 72 years in the CALGB-8421
protocol, AZA-MDS-001 trial and the Dutch named pa-
tient programme, respectively) [23, 36, 37]. As a side note,
the median OS of 24.5 months obtained in patients with
AML20–30 in the AZA-MDS-001 trial is exceptionally
long [36], and thus far, no other group has been able to
find similarly long OS times in elderly AML patients,
no matter which treatment was investigated, and no
matter which bone marrow blast count was used as
cut-off (Table 7 [24, 38–48]). Median OS of patients re-
ceiving conventional care regimen in the AZA-MDS-001
trial was also extraordinarily high (16.0, 17.0, 14.2 and
13.4 months for all conventional care regimen combined,
low-dose cytarabine, IC and best supportive care (BSC), re-
spectively) [36], indicating that patient selection may have
favoured improved survival. The lack of clinical trials allow-
ing direct comparison of the efficacy of azacitidine in
AML20–30 vs AML30+ is likely due to the requirements
imposed by the registration agencies. A randomised trial
performed exclusively in AML30+ [24] was requested in
order to widen the registration indication of azacitidine to
include AML30+, thus eliminating the possibility of a direct
comparison of the efficacy of azacitidine in AML20–30 vs
AML30+. Our data show the first direct comparison of
these two patient groups and reveal similar baseline and
treatment characteristics, ORR and OS for patients with
AML20–30 (n = 79) vs AML30+ (n = 111) treated with
azacitidine front-line, respectively. We further confirm
the efficacy of azacitidine in the subset of patients with
AML30+, with a median OS of 10.9 months observed in
our cohort (n = 111), which was similar to that observed
in the recently published phase III clinical trial AML-001
(10.4 months; n = 241) [24]. Thus, patients with AML30+
seem to derive similar clinical benefit from azacitidine in
terms of OS prolongation, as patients with AML20–30.
In AML patients, the presence of MRF has been shown
to be associated with adverse clinical outcome [49–51].
Although previous studies reporting on azacitidine in the
front-line setting included patients with MRF, outcomes
were not reported separately. We demonstrate for the first
time that the presence of MRF has no adverse effect on
OS of elderly patients treated with azacitidine front-line
(Fig. 2a–c). This seems to be of clinical relevance in light
of adverse outcomes observed with front-line IC in
patients with secondary AML compared with de novo AML
(6.8 vs 14.8 months; p < 0.05 [52]; 8.6 vs 23.0 months; p <
0.001 [53]). Another trial performed in patients with AML-
MRF reported a median OS of only 14 months in young pa-
tients (<60 years) treated with an IC regimen [54]. The me-
dian OS of 13.2 months observed in our elderly AML-MRF
patients (median age 77 years) indicates that these patients
benefit from treatment with azacitidine (Fig. 2c).
We also present the first direct comparison of baseline
factors, treatment-related factors and outcomes of patients
with MDS-RAEB-I, MDS-RAEB-II, AML20–30 and
AML30+ treated with azacitidine front-line (Tables 1,
2, 3, 4 and 5). Our data indicate that patients with
AML20–30 have comparable baseline, treatment and
response characteristics to patients with MDS-RAEB-II or
AML30+ but behave more like AML30+ than MDS-
RAEB-II with respect to OS (Table 4; Fig. 1a). This implies
that the WHO reclassification of patients with 20–30 %
bone marrow blasts from MDS-RAEB-t to AML seems
appropriate in patients receiving azacitidine as front-line
agent. Near identical observations have been made in
patients treated with decitabine in a pooled sub-analysis
Table 5 WHO Classification: OS of patients with MDS or
AML-MRF receiving AZA front-line













































aHR = 1.247; 95 % CI 1.118–1.392
bHR = 1.551; 95 % CI 1.032–2.331
WHO World Health Organization, OS overall survival, MDS myelodysplastic
syndrome, AML acute myeloid leukaemia, MRF MDS-related features, AZA
azacitidine, CI confidence interval, RAEB refractory anaemia with excess blasts,
HR hazard ratio
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of two clinical trials, which demonstrated significantly
shorter median OS in patients with AML20–30 compared
with patients with higher-risk MDS (9.0 vs 16.6 months;
p = 0.021), respectively [34].
The effect of time from diagnosis to treatment (TDT)
on overall survival of patients with MDS and AML remains
obscure. In high-risk MDS patients including RAEB-t
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Fig. 2 Effect of MRF on OS of patients with a AML30+, b AML20–30 and c AML (all patients)
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lenalidomide or others), median TDT varied from
4.8 months [55] to >1 year [15], whereas separate ana-
lyses of RAEB-t and RA/RARS by others revealed a signifi-
cantly shorter median TDT for RAEB-t (7.3 vs. 18.3 months,
p = 0.021) [34], and others found a significantly shorter TDT
for those MDS patients that eventually transformed to AML
(10.8 months) as compared with those who did not
(20.8 months) [35]. These reports do not allow conclusions
as to why shorter TDT have been observed in patients with
higher-risk MDS and RAEB-t. One might speculate, how-
ever, that these patients are perceived as being in more dire
need of treatment (due to higher bone marrow blasts, worse
cytopenias and/or adverse cytogenetics) and are more likely
to receive treatment soon after initial diagnosis. This is
backed up by our own observations, which show a progres-
sively shorter time from initial cytopenias (4.2, 2.8, 1.6 and
0.9 months) as well as initial diagnosis (3.0, 1.6, 0.6 and
0.5 months) to azacitidine treatment start for patients with
RAEB-I, RAEB-II, AML20–30 and AML30+, respectively
(Additional file 3: Table S3). Whether earlier treatment initi-
ation in higher-risk MDS and AML20–30 translates into
earlier response, longer response duration, or possibly results
in a survival advantage, remains unknown at this time point.
Even in the event that a correlation between TDT and out-
come could be shown, it would still need to be clarified,
whether this might also reflect a more aggressive underlying
biology and kinetics of the disease.
There are not many studies that address the topic of
TDT in AML, but those that did were all performed ex-
clusively in patients treated with intensive chemotherapy
approaches, with (partially) controversial results [53, 56–
59]. Most results however, do indicate that longer TDT
is associated with worse prognosis, i.e. lower response
rates and shorter OS [56–59], and it was concluded that
initiating therapy as soon as possible after diagnosis might
be a potential strategy to improve OS in AML patients
[59]. Whether this can be translated to patients treated
with hypomethylating agents remains to be shown.
In this report, we have shown that patients with AML20–
30 treated with azacitidine front-line should be regarded as
‘true AML’. In line with the above [56–59], we believe that
treatment should thus be initiated without delay.
Table 6 FAB classification: OS of patients with MDS or AML
receiving azacitidine front-line
































aHR = 1.248; 95 % CI 1.249, 1.634
bHR = 2.185; 95 % CI 1.557, 3.066
FAB French-American-British, OS overall survival, MDS myelodysplastic
syndrome, AML acute myeloid leukaemia, CI confidence interval, RAEB
refractory anaemia with excess blasts, HR hazard ratio
Table 7 Elderly AML front-line treatment options and median OS times
Treatment N Age, years Median age, years CR/CRi, % OS, mo Phase Ref
Untreated 3367 ≥65 77 n.g. 2 Retrosp. [39]
HU+/-ATRA 99a >60 74 1 ~3 III [43]
HD-LEN 33 >60 71 30 4 II [45]
LD-AraC+/-ATRA 103a >60 74 18 <5 III [43]
CFA 112 >60 71 46 9.4 II [40]
CFA + LD-AraC 54 >60 71 63 11.4 II [42]
CFA + LD-AraC/DAC 60 >60 70 58 12.7 II [44]
CFA + LD-AraC/DAC 118 >60 68 60 11.1 II [44]
Allo-SCT 46 ≥65 67 n.g. 22 Retrosp. [39]
Intensive CTX 1856 ≥65 74 n.g. 6 Retrosp. [39]
Intensive CTX (3 + 7) 416 >65 67 57 12 III [41]
BSC↔ allo-SCT 352 ≥60 n.g. n.g. 9.0 Retrosp. [47]
BSC↔ allo-SCT 5480 ≥65 78 n.g. 3.0 Retrosp. [39]
DAC (DACO-16) 238 >65 74 18 7.7 III [48]
AZA (AZA-AML-001) 241 >65 75 28 10.4 III [24]
AZA-AAR 193 >17 77 18 12.6 Retrosp. [46]
AZA + LEN 42 >60 74 28 15.9 I/II [38]
aIncluded 14 patients with high-risk MDS
n.g.CR complete response, CRi CR with incomplete blood count recovery, OS overall survival, n.g. not given, HU hydroxyurea, ATRA all trans retinoic acid, HD high-
dose, LEN lenalidomide, LD-AraC low-dose cytarabine, CFA clofarabine, DAC decitabine, allo-SCT allogeneic stem cell transplantation, CTX chemotherapy, BSC best
supportive care, AZA azacitidine, AML acute myeloid leukaemia, AAR Austrian Azacitidine Registry, MDS myelodysplastic syndrome
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For decades, it has remained controversial whether
AML20–30 (formerly MDS-RAEB-t) potentially follows
a more benign disease trajectory than AML30+ and
whether consideration should be given to possible retention
of MDS-RAEB-t as a separate disease entity distinct from
MDS and AML [7, 16–19, 22, 31, 33, 34, 60–69]. The fact
that the term ‘RAEB-t’ is still used in very recent reports on
the efficacy of decitabine in patients with RAEB-t [34, 70]
shows the actuality of this issue. In an effort to clarify
this matter for elderly patients treated with azacitidine
front-line, we reclassified our cohort according to the
FAB classification. Patients with MDS-RAEB-t had sig-
nificantly worse OS than patients with MDS-RAEB, but
similar survival to patients with AML30+ (Table 6;
Fig. 1c). We thus show that the FAB disease category
MDS-RAEB-t does not adequately distinguish risk cat-
egories or behave as an entity distinct from both MDS
and AML with regard to patient outcome. In contrast,
and as mentioned above, the WHO classification of MDS
and AML adequately distinguished patient categories with
distinct outcomes (13.1 vs 18.9 months for AML20–30 vs
MDS-RAEB-II, p = 0.010; Table 4 and Fig. 1a). We con-
clude that the elimination of the FAB category RAEB-t,
and its incorporation within the WHO categories
MDS-RAEB-II and AML, seems justified in elderly AML
patients treated with azacitidine front-line.
In our cohort, the distinction between MDS-RAEB-I
or MDS-RAEB-II could not separate groups with differ-
ing OS (23.7 vs 18.9 months, p = 0.302; Table 4 and
Fig. 1a). Of note, the IPSS [8] gave more weight to the
bone marrow blast threshold between 10 and 11 % (+1.0
additional score points for 11–20 %) than to the thresh-
old between 20 and 21 % (+0.5 additional score points).
Similarly, the revised IPSS [71] conceded 1 additional
score point for patients with ≥11 % bone marrow blasts
but gave no further weight to bone marrow blast per-
centages >11 % (0 additional score points). Thus, while
we could not confirm the capability of the WHO classifica-
tion of MDS-RAEB-I and MDS-RAEB-II for distinguishing
differing risk categories, we could confirm the weighting
for bone marrow blasts chosen by the IWG for the progno-
sis of MDS.
Conclusions
We have demonstrated (i) the promising potential of
azacitidine as front-line treatment for patients with
AML, irrespective of bone marrow blast count and/or
presence of MRF; (ii) the adequate categorisation of pa-
tients with 20–30 % bone marrow blasts as AML and
(iii) we have addressed some topics of the WHO 2008
classification of MDS and AML; in particular, we con-
firm the validity of the WHO classification of MDS and
AML, and that the former FAB category MDS-RAEB-t
was correctly consolidated under the diagnosis of AML
in patients treated with azacitidine front-line. Patients
with AML20–30 should thus be regarded as ‘true AML’,
and in our opinion, treatment should be initiated with-
out delay. Our results should thus pave the way for the
accurate classification and prognostication, as well as




The AAR of the ‘Arbeitsgemeinschaft Medikamentöse
Tumortherapie’ (AGMT) Study Group is a multicen-
tre database, initiated to gain a comprehensive view
of the use, safety and efficacy of azacitidine in a
broad range of patients with MDS or AML in a ‘real-
world’ clinical practice setting (ClinicalTrials.gov:
NCT01595295) [61, 62, 72–80]. Ethics Committee ap-
proval was obtained on February 06, 2009. Seventeen
centres participated in the registry. The only inclusion
criteria were a diagnosis of MDS or AML according to
WHO criteria and treatment with at least one dose of
azacitidine. No formal exclusion criteria existed, as the
aim was to include all patients treated with azacitidine,
irrespective of age, comorbidities and/or number of pre-
vious lines of treatment. Treatment indication and the
decision to offer azacitidine, as well as dose, schedule and
dose reductions/escalations were exclusively based on the
risk/benefit estimation of the treating physician. Due to a
lack of treatment alternatives, AML patients with >30 %
bone marrow blasts were also offered treatment with
azacitidine. They were informed of off-label use and gave
written informed consent. Data were entered into elec-
tronic case report forms (eCRFs) by physicians and/or
trained clinical trial personnel at the respective centres.
All eCRFs were monitored centrally in order to ensure
data integrity and plausibility. Missing data were low. If
necessary, centres received queries specifying incomplete
data or questions to reconfirm data.
This analysis selected patients with MDS-RAEB-I/II or
AML receiving azacitidine as front-line therapy, which was
defined as absence of prior disease-modifying treatment.
Only prior treatment with growth factors (granulocyte-col-
ony stimulating factor, erythropoietin, thrombopoietin-
stimulating agents) and/or prior iron chelators was allowed.
Patients treated with prior hydroxyurea, immunosuppres-
sive treatment (cyclosporin A, ATG), low-dose cytarabine,
revlimid, thalidomide, tyrosine kinase inhibitors and/or
intensive chemotherapy for MDS or AML were considered
as pretreated. Assessment of response, safety and end-
points, and statistical analyses within the AAR were per-
formed as previously described [61, 62, 73]. The IPSS
cytogenetic risk score was established for and validated in
patients with MDS and is not commonly used to stratify
cytogenetic risk in AML patients. However, we used this
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score for both MDS and AML patients, in order to be able
to compare frequencies of certain karyotypes (not actual
cytogenetic risk) across these patient groups. Response was
assessed according to current criteria. ORR included CR,
CyCR, CRi and PR. HI and achievement of TI were
assessed according to IWG 2006 criteria [13]. HI and TI
are considered to be a form of response in MDS [13], but
not in the current AML response criteria [28, 81]. HI and
TI were, however, also assessed in AML patients, in order
to compare the (putative) efficacy of azacitidine across dis-
ease entities, as has been done by several clinical trials [23,
36]. Adverse events were assessed according to the Com-
mon Terminology Criteria for adverse events (CTCAEv.4)
(http://evs.nci.nih.gov/ftp1/CTCAE/About.html). TEAEs
were defined as new or worsening AEs between the time
of first dose of azacitidine to the end of the safety follow-
up period (28 days after the last dose of azacitidine).
Treatment-emergent haematological toxicity was calcu-
lated from differential blood counts and transfusions
status of all cycles for each patient (no missing data).
Statistics
OS as of azacitidine start was assessed using the
Kaplan–Meier method. Data-cleaning and survival-
analysis cut-off date was 18 June 2015, for AML patients
and 17 August 2015, for MDS patients. Univariate ana-
lyses were performed with log-rank tests. Cox-regression
stratified on the various factors was used for univariate
analyses of risk-factors for OS. Baseline characteristics
were compared using the chi-squared test. Analyses
were performed with SPSS. No adjustments were made
for multiple testing.
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